Security
MDxHealth SA Ordinary Shares · MDXH
MDXHNASDAQCommon stockCurrentCIK 1872529Updated Nov 2, 2026
MDXH price & chart
Loading TradingView…
NASDAQ:MDXH on TradingView ↗About the company
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
Financials
FY 2025 · USDSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -33,519,000Source | -38,069,000Source | -43,100,000Source | -44,044,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | 2,320,000Source | -3,226,000Source | -1,683,000Source | -5,122,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | 550,000Source | 458,000Source | 20,000Source | 3,973,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 2,211,000Source | 1,725,000Source | 665,000Source | 867,000Source |
| DividendsPaidOrdinarySharesPerShareEUR/shares | — | — | — | 0.85Source |
| GeneralAndAdministrativeExpenseUSD | 26,928,000Source | 22,801,000Source | 23,010,000Source | 23,539,000Source |
| GoodwillUSD | 38,948,000Source | 35,926,000Source | 35,926,000Source | 35,926,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 9,730,000Source | 6,702,000Source | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 2,322,000Source | 1,883,000Source | 1,610,000Source | 1,358,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 24,250,000Source | 53,011,000Source | — | 34,291,000Source |
| ProceedsFromIssuingSharesUSD | — | 40,739,000Source | 39,599,000Source | 0Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | 971,000Source | 2,272,000Source | 1,374,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 324,000Source | 39,540,000Source | 250,000Source | 1,358,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source |
| Total RevenueUSD | 107,875,000Source | 90,049,000Source | 70,193,000Source | 37,054,000Source |
| Additional Financial Items | ||||
| AdministrativeExpenseUSD | — | — | — | 3,700,000Source |
| ApplicableTaxRatenumber | — | — | — | 0.25Source |
| BasicEarningsLossPerShareUSD per share | -0.67Source | -1.16Source | -1.66Source | -0.28Source |
| DepreciationAndAmortisationExpenseUSD | — | — | — | 965,000Source |
| DilutedEarningsLossPerShareUSD per share | -0.67Source | -1.16Source | 1.66Source | 0.28Source |
| EmployeeBenefitsExpenseUSD | — | 2,479,000Source | — | — |
| FinanceCostsUSD | 23,030,000Source | 15,322,000Source | 18,342,000Source | 6,144,000Source |
| FinanceIncomeUSD | 2,062,000Source | 2,357,000Source | 2,570,000Source | — |
| GeneralAndAdministrativeExpenseUSD | 26,928,000Source | 22,801,000Source | 23,010,000Source | 23,539,000Source |
| GrossProfitUSD | 69,633,000Source | 55,141,000Source | 43,929,000Source | 19,219,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | -1,857,000Source | 382,000Source | 1,000Source | 0Source |
| InterestExpenseUSD | 786,000Source | 384,000Source | 355,000Source | 314,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 786,000Source | 392,000Source | 284,000Source | 314,000Source |
| OtherEmployeeExpenseUSD | — | 224,000Source | — | — |
| OtherFinanceCostUSD | 228,000Source | — | 216,000Source | 219,000Source |
| OtherOperatingIncomeExpenseUSD | 993,000Source | -624,000Source | -461,000Source | 559,000Source |
| ProfessionalFeesExpenseUSD | — | — | 710,000Source | 1,259,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | -33,519,000Source | -38,069,000Source | -43,100,000Source | -44,044,000Source |
| ProfitLossBeforeTaxUSD | -35,376,000Source | -37,687,000Source | -43,099,000Source | -44,044,000Source |
| ProfitLossFromOperatingActivitiesUSD | -14,408,000Source | -24,722,000Source | -27,327,000Source | -37,900,000Source |
| ResearchAndDevelopmentExpenseUSD | 10,350,000Source | 10,552,000Source | 6,376,000Source | 7,557,000Source |
| RevenueFromInterestUSD | 1,500,000Source | 1,100,000Source | — | — |
| SellingExpenseUSD | — | — | 11,200,000Source | 8,800,000Source |
Offerings
Registration 333-292463
Filing attachments
ea031016501ex99-1.htm · 6-K · 2026-10-30
Exhibit 99.1 Unofficial English translation - For informational purposes only MDxHealth SA Limited Liability Company ( société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) INVITATION extraordinary GENERAL MEETING to be held on Thursday, November 19, 2026, at 4:00 p.m. The holders of securities issued by MDxHealth SA (the “Company”) are invited to the extraordinary general shareholders…
Read attachment ↗ea031016501ex99-2.htm · 6-K · 2026-10-30
Exhibit 99.2 MDxHealth SA CAP Business Center Rue d’Abhooz, 31 B-4040 Herstal - Belgium E. info@mdxhealth.com www.mdxhealth.com October 30, 2026 Dear Shareholder, Re: Extraordinary general shareholders’ meeting of MDxHealth SA to be held on November 19, 2026 ──────────────────────────────────────────────────────────────────────────────────────────────────────── On behalf of the Board of Directors of MDxHealth SA (the “Company”), you are cordially invited to attend the ex…
Read attachment ↗ea030882401ex99-1.htm · 6-K · 2026-10-16
Exhibit 99.1 MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance IRVINE, CA - October 15, 2026 (GlobeNewswire) - MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced preliminary unaudited revenue from continuing operations for the third quarter ended September 30, 2026, and suspends its full-year 2026 revenue guidance of $110 - 115 million. The Company expects to repo…
Read attachment ↗ex99-1.htm · SCHEDULE 13D/A · 2026-10-15
Schedule I Date Number Price of Shares Sold per Share ($) ─────────────────────────────────────────────────── 9/17/26 144,979.0000 $0.6733 9/18/26 54,661.0000 $0.6339 9/21/26 74,811.0000 $0.6040 9/22/26 43,819.0000 $0.5909 9/23/26 29,170.0000 $0.5909 9/24/26 9,927.0000 $0.5900 9/25/26 51,975.0000 …
Read attachment ↗ea030428401ex99-1.htm · 6-K · 2026-09-03
Exhibit 99.1 2026 INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 2 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 4 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 4 2. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 5 3. CONDENSED UNAUDITED C…
Read attachment ↗ea030197501ex99-1.htm · 6-K · 2026-08-13
Exhibit 99.1 Mdxhealth Reports Second Quarter 2026 Financial Results Second quarter revenue growth of 16% to $27.2 million Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California - August 13, 2026 (GlobeNewswire) - MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leader in urology-focused precision diagnostics, today announced its financial results for the second quarter ended June 30, 2026. Michael K. McGarrity, CEO of mdxhealth, commented: “We delivered s…
Read attachment ↗